The COVID-19 pandemic has brought to light the need for fast and sensitive detection methods to prevent the spread of pathogens. The scientific community is making a great effort to design new molecular detection methods suitable for fast point-of-care applications. In this regard, a variety of approaches have been developed or optimized, including isothermal amplification of viral nucleic acids, CRISPR-mediated target recognition, and read-out systems based on nanomaterials.
We present a fast, reliable and easy to scale-up colorimetric sensor based on gold nanoparticles (AuNPs) to detect the sequences coding for the RdRp, E, and S proteins of SARS-CoV-2. The optimization of the system (so-called “the sensor”) includes the evaluation of different sizes of nanoparticles, sequences of oligonucleotides and buffers. It is stable for months without any noticeable decrease in its activity, allowing the detection of SARS-CoV-2 sequences by the naked eye in 15 min. The efficiency and selectivity of detection, in terms of significative colorimetric changes in the solution upon target recognition, are qualitatively (visually) and quantitatively (absorbance measurements) assessed using synthetic samples and samples derived from infected cells and patients. Furthermore, an easy and affordable amplification approach is implemented to increase the system's sensitivity for detecting high and medium viral loads (≥103 - 104 viral RNA copies/μl) in patient samples. The whole process (amplification and detection) takes 2.5 h. Due to the ease of use, stability and minimum equipment requirements, the proposed approach can be a valuable tool for the detection of SARS-CoV-2 at facilities with limited resources.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, largely due to its poor response to chemotherapy and the development of drug resistance. Survivin (BIRC5), an inhibitor of apoptosis frequently overexpressed in PDAC, contributes to tumor cell survival and gemcitabine resistance, making it an attractive therapeutic target. Here, we developed a lipid nanoparticle (LNP)-based platform for the delivery of preassembled spCas13b ribonucleoproteins (RNPs) to achieve transient and sequence-specific RNA silencing in pancreatic cancer cells. We optimized ionizable lipid formulations for Cas13b RNP encapsulation and identified a formulation achieving approximately 80% encapsulation efficiency, with sustained colloidal stability and gene-silencing activity during seven days of storage at 4°C. LNP-delivered Cas13b RNPs efficiently silenced endogenous BIRC5 in three pancreatic cancer cell lines, reducing survivin protein levels and inducing apoptosis. In gemcitabine-resistant PANC-1 cells, BIRC5 silencing synergistically enhanced the cytotoxic effect of gemcitabine in vitro. This therapeutic combination was further evaluated in a PANC-1 xenograft model, where only the combined administration of BIRC5-targeting Cas13b RNP-LNPs and gemcitabine significantly inhibited tumor growth, without apparent systemic toxicity. Intratumoral administration also restricted nanoparticle distribution to the injected tumors. These findings establish LNP-mediated delivery of Cas13b RNPs as a new strategy for transient RNA-targeted therapy and provide proof of concept for combining survivin silencing by Cas13b with chemotherapy to address gemcitabine resistance in pancreatic cancer.